<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-09-20T00:59:06Z</responseDate><request verb="GetRecord" identifier="oai:dspace.mit.edu:1721.1/143406" metadataPrefix="dim">https://dspace.mit.edu/server/oai/request</request><GetRecord><record><header><identifier>oai:dspace.mit.edu:1721.1/143406</identifier><datestamp>2022-06-16T03:35:06Z</datestamp><setSpec>com_1721.1_7582</setSpec><setSpec>com_1721.1_7581</setSpec><setSpec>col_1721.1_131022</setSpec></header><metadata><dim:dim xmlns:dim="http://www.dspace.org/xmlns/dspace/dim" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
   <dim:field mdschema="dc" element="contributor" qualifier="advisor">Vander Heiden, Matthew</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="author">Moomau, Christine Anne</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="department">Massachusetts Institute of Technology. Department of Biology</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="accessioned">2022-06-15T13:18:36Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="available">2022-06-15T13:18:36Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="issued">2022-02</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="submitted">2022-05-19T18:04:37.413Z</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">https://hdl.handle.net/1721.1/143406</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="abstract">Phenotypic variability is a noted feature of human trisomies. This is exemplified by the presentation of trisomy 21 (Down syndrome). The incidence of and severity of clinical features are highly variable in individuals with Down syndrome. These differences have long been attributed to genetic differences within the population altering the likelihood that particular phenotypes will develop. However, work in yeast and mouse models of aneuploidy suggest that phenotypic variability can be a consequence of aneuploidy itself in the absence of genetic heterogeneity.&#xd;
&#xd;
By studying variability in induction of the GAL1-10 promoter in aneuploid strains of budding yeast, S. cerevisiae, we show that altering gene dosage can lead to variability. The endocytosis defect caused by a specific aneuploidy (Disome IX) is sufficient to increase variability in the GAL signaling pathway. The addition of a second copy of chromosome IX in haploid yeast increases the dosage of multiple genes involved in endocytosis. This leads to an endocytic defect that impacts the cell surface localization of hexose transporters, which ultimately leads to variability in uptake of hexose sugars and thus variability in induction of the GAL1-10 promoter.</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degree">Ph.D.</dim:field>
   <dim:field mdschema="dc" element="publisher">Massachusetts Institute of Technology</dim:field>
   <dim:field mdschema="dc" element="rights">In Copyright - Educational Use Permitted</dim:field>
   <dim:field mdschema="dc" element="rights">Copyright MIT</dim:field>
   <dim:field mdschema="dc" element="rights" qualifier="uri">http://rightsstatements.org/page/InC-EDU/1.0/</dim:field>
   <dim:field mdschema="dc" element="title">Exploring the role of aneuploidy in phenotypic variability</dim:field>
   <dim:field mdschema="dc" element="type">Thesis</dim:field>
   <dim:field mdschema="dc" element="format" qualifier="mimetype">application/pdf</dim:field>
   <dim:field mdschema="mit" element="thesis" qualifier="degree">Doctoral</dim:field>
   <dim:field mdschema="thesis" element="degree" qualifier="name">Doctor of Philosophy</dim:field>
   <dim:field mdschema="dspace" element="entity" qualifier="type">Publication</dim:field>
   <dim:field mdschema="others" element="access-status">unknown</dim:field>
   <dim:field mdschema="others" element="access-status">unknown</dim:field>
   <dim:field mdschema="cerif" element="openaire" authority="" confidence="-1">&lt;Publication xmlns="https://www.openaire.eu/cerif-profile/1.1/" id="64f9a4a6-0070-433d-a09d-66dc5ebf1f36">
	&lt;Type xmlns="https://www.openaire.eu/cerif-profile/vocab/COAR_Publication_Types">http://purl.org/coar/resource_type/c_1843&lt;/Type>
   	&lt;Title>Exploring the role of aneuploidy in phenotypic variability&lt;/Title>
   	&lt;PublishedIn>
    	&lt;Publication>
      	&lt;/Publication>
   	&lt;/PublishedIn>
   	&lt;PublicationDate>2022-02&lt;/PublicationDate>
   	&lt;Authors>
      	&lt;Author>
        	&lt;DisplayName>Moomau, Christine Anne&lt;/DisplayName>
         	&lt;Affiliation>
         		&lt;OrgUnit>
         		&lt;/OrgUnit>
         	&lt;/Affiliation>
      	&lt;/Author>
	&lt;/Authors>
   	&lt;Editors>
	&lt;/Editors>
    &lt;Publishers>
        &lt;Publisher>
            &lt;DisplayName>Massachusetts Institute of Technology&lt;/DisplayName>
            &lt;OrgUnit />
        &lt;/Publisher>
    &lt;/Publishers>
    &lt;License>http://rightsstatements.org/page/InC-EDU/1.0/&lt;/License>
   	&lt;Abstract>Phenotypic variability is a noted feature of human trisomies. This is exemplified by the presentation of trisomy 21 (Down syndrome). The incidence of and severity of clinical features are highly variable in individuals with Down syndrome. These differences have long been attributed to genetic differences within the population altering the likelihood that particular phenotypes will develop. However, work in yeast and mouse models of aneuploidy suggest that phenotypic variability can be a consequence of aneuploidy itself in the absence of genetic heterogeneity.&#xd;
&#xd;
By studying variability in induction of the GAL1-10 promoter in aneuploid strains of budding yeast, S. cerevisiae, we show that altering gene dosage can lead to variability. The endocytosis defect caused by a specific aneuploidy (Disome IX) is sufficient to increase variability in the GAL signaling pathway. The addition of a second copy of chromosome IX in haploid yeast increases the dosage of multiple genes involved in endocytosis. This leads to an endocytic defect that impacts the cell surface localization of hexose transporters, which ultimately leads to variability in uptake of hexose sugars and thus variability in induction of the GAL1-10 promoter.&lt;/Abstract>
	&lt;Access xmlns="http://purl.org/coar/access_right" 
    >
    &lt;/Access>
&lt;/Publication>
</dim:field>
</dim:dim>
</metadata></record></GetRecord></OAI-PMH>